Rajshree Kt
About Rajshree Kt
Rajshree Kandadai Business Development
Rajshree Kandadai is an experienced professional in business development, with over 20 years of expertise in roles spanning from licensing and corporate strategy to alliance management. Currently, she plays a crucial role in advancing business development initiatives.
Corporate Strategy and Licensing Experience at Mass General Brigham
Rajshree Kandadai has a notable background at Mass General Brigham (MGB) Innovation, where she previously led licensing activities for oncology assets. Her responsibilities extended across several institutions, including Brigham and Woman’s Hospital, Mass General Hospital, and the MGH Vaccine and Immunotherapy Center. Her tenure was marked by driving several high-value transactions, showcasing her adeptness in corporate strategy and licensing.
Rajshree Kandadai's Role at Aurigene Oncology
From 2010 to 2019, Rajshree Kandadai served as Senior Director of Corporate Development and Strategy at Aurigene Oncology. During this time, she established more than 15 collaborations with prominent pharma and biotech companies in the U.S., Europe, and Japan. Her efforts at Aurigene resulted in over $250 million in realized revenues, highlighting her significant impact on the company's strategic growth.
Equity Research Analyst Career
Rajshree Kandadai built a strong foundation in the financial sector as a healthcare equity research analyst. She served at UBS ISC, where she led the healthcare equity research team, and at HSBC, where she covered the U.S. healthcare sector. Her analytical skills and comprehensive sector knowledge informed her later success in business development roles.
Rajshree Kandadai Education Background
Rajshree Kandadai holds a Master’s degree in hospital management, providing her with a robust foundation in healthcare administration. Additionally, she earned a B.S. in microbiology, which complements her extensive professional experience in the healthcare and biotech sectors.